The World Health Organization has warned that an Ebola outbreak caused by the rare Bundibugyo virus in the Democratic Republic of the Congo is growing exponentially, passing 5,000 cases with close to 2,500 deaths as authorities prepare clinical trials for an experimental vaccine.
An Unprecedented Spread Across Central Africa
The outbreak in the Democratic Republic of the Congo continues to accelerate at a rate that has alarmed public health officials worldwide. Following an emergency meeting, WHO Director-General Tedros Adhanom Ghebreyesus called on the international community to assist in containment efforts as total infections surpassed 5,000 cases.
Marking the seventeenth Ebola epidemic in the country’s history, the current crisis has exceeded the death toll of the 2018 to 2020 outbreak, which claimed 2,299 lives.
The World Health Organization warned that the disease was growing exponentially
in the north and east of the country. Julien Harneis, the WHO’s Ebola co-ordinator, told reporters that half of the total deaths occurred in a recent 20-day window.
The geographical spread now covers an area larger than France. A new report by Save the Children indicates that at least 180 Congolese children have lost both parents or caregivers since the emergency began.
Tracking a Bundibugyo Strain With No Approved Vaccines
Unlike previous major epidemics driven by the Zaire species of the virus, the current crisis stems from the Bundibugyo species. This strain is exceptionally rare, with only two known prior outbreaks documented before the current emergency.
A central complication for medical teams is the absence of approved treatments or vaccines specifically targeting the Bundibugyo virus. While the Ervebo vaccine protects against the Zaire species, currently there are no proven vaccines or treatments for Bundibugyo.
Retrospective analysis shows the epidemic began spreading three months earlier in February, but initial infections were frequently misdiagnosed as malaria and typhoid because early symptoms mirror those common illnesses.
Efforts to mount an effective response face severe obstacles, including ongoing armed conflict in mineral-rich eastern regions, community distrust of health workers, informal healthcare networks, and traditional burial practices.
Clinical Trials and Vaccine Development Timelines
Public health authorities are moving forward with experimental immunization strategies. The World Health Organization confirmed that 20,000 doses will be deployed in a clinical trial to test effectiveness against the Bundibugyo species, alongside 50,000 doses designated for front-line health workers.
Simultaneously, alternative vaccine candidates are advancing through early development stages. The first volunteer to receive an experimental vaccine for this strain received a jab in the United Kingdom, utilizing doses produced by scientists at Oxford University and manufactured in India.
WHO adviser Moorthy explained that a second candidate vaccine, based on the same platform as the AstraZeneca Covid-19 vaccine, is currently being manufactured. However, there was no animal data to support its effectiveness at this stage, and clinical trials could take two to three months depending on preclinical results.
For the most promising candidate comparable to existing Zaire preventatives, expert estimates indicate it will likely take six to nine months before it is ready for broader deployment.
Regional Spillover and Conflict Complications
The international dimension of the outbreak emerged early when the World Health Organization determined the situation constituted a public health emergency of international concern. Two laboratory-confirmed cases with no apparent link to each other were reported in Kampala, Uganda, within 24 hours after individuals traveled from the Democratic Republic of the Congo.
Inside the DRC, territorial control by armed groups adds layers of operational friction. The M23 rebel group, which controls parts of North Kivu province, announced a one-month suspension of shared taxis and passenger boats between government-held and rebel-held areas following confirmed cases in a rebel-controlled village.
While rebel authorities previously declared their zones Ebola-free in late June, the new transit restrictions aim to halt transmission chains. WHO medic Thierno Balde emphasized that local mobilization must target high-mobility groups, noting that motorbike riders are now a core focus of response efforts due to their role in transporting patients and bodies.
International Funding Gaps and Scale of Need
With transmission chains active across multiple provinces and international borders, health officials stress that ending the epidemic depends entirely on identifying and breaking every remaining link in the infection chain.
